SAFC strengthens CHOZN biopharmaceutical portfolio
Two novel host cell lines are now commercially available as custom products
Sigma-Aldrich's SAFC Commercial services business unit, has engineered additional traits into its CHOZN platform cell line, increasing its products and services.
Two novel host cell lines have been added to the CHOZN portfolio. The first is the CHOZN GS-/- host trait stacked with a knockout of the MGAT1 gene function that results in early termination of the N-glycan pathway and enables the expression of recombinant proteins with homogeneous high Man5 glycan profiles. SAFC says this is useful for protein crystallography studies as well as for the expression of biotherapeutics that target mannose receptors.
The second novel cell line is the CHOZN GS-/- host trait stacked with knockouts of the CMAH and GGTA gene sequences. This enables the expression of recombinant proteins that do not contain the antigenic alpha-gal and Neu5Gc moieties on the glycan structures and makes them capable of producing potentially safer therapeutic proteins.
The new products are now commercially available from SAFC as custom products.
